Bruker BioSciences Non-Affiliated Shareholders Overwhelmingly Approve Acquisition of Bruker BioSpin Group

  
    
  
  
    
      After the Company’s Special Stockholders 
      Meeting held this morning in Boston, Bruker BioSciences Corporation 
      (NASDAQ: BRKR) announces that its stockholders have approved the 
      acquisition of the companies comprising the Bruker BioSpin Group.
    
    
      At today’s Special Meeting all proposals were 
      approved with overwhelming majorities by the Bruker BioSciences 
      stockholders. In particular, the three proposals for the acquisition of 
      the Bruker BioSpin Group companies were each approved by a majority of 
      greater than 99% of the BRKR shareholders not affiliated with the 
      controlling shareholders of BRKR and who voted at the meeting.
    
    
      In addition to approving the acquisition of the Bruker BioSpin Group, 
      stockholders approved amendments to the Company’s 
      certificate of incorporation to, among other things, change the name of 
      the Company to ‘Bruker Corporation’. 
      Moreover, Dr. Tony W. Keller and Dirk D. Laukien, Ph.D. were elected to 
      serve as directors of Bruker Corporation.
    
    
      Frank Laukien, President and CEO of Bruker BioSciences, stated: “We 
      are very pleased to receive this clear vote and mandate from our 
      non-affiliated shareholders to move forward with the acquisition of the 
      Bruker BioSpin Group, which is now expected to close in February. The 
      Bruker BioSpin Group is very complementary to Bruker BioSciences and the 
      transaction should allow us to expand our combined market reach, 
      leverage the Bruker brand, and enhance our ability to grow our 
      profitability and cash flows.”
    
    
      CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES
    
    
      Any statements contained in this press release that do not describe 
      historical facts may constitute forward-looking statements as that term 
      is defined in the Private Securities Litigation Reform Act of 1995. Any 
      forward-looking statements contained herein are based on current 
      expectations, but are subject to a number of risks and uncertainties. 
      The factors that could cause actual future results to differ materially 
      from current expectations include, but are not limited to, risks and 
      uncertainties relating to the integration of businesses we have acquired 
      or may acquire in the future, changing technologies, product development 
      and market acceptance of our products, the cost and pricing of our 
      products, manufacturing, competition, dependence on collaborative 
      partners and key suppliers, capital spending and government funding 
      policies, changes in governmental regulations, intellectual property 
      rights, litigation, and exposure to foreign currency fluctuations. These 
      and other factors are identified and described in more detail in our 
      filings with the SEC, including, without limitation, our annual report 
      on Form 10-K for the year ended December 31, 2006, our most recent 
      quarterly reports on Form 10-Q and our current reports on Form 8-K. We 
      disclaim any intent or obligation to update these forward-looking 
      statements other than as required by law.